Dcf Advisers, LLC Impel Pharmaceuticals Inc Call Options Transaction History
Dcf Advisers, LLC
- $242 Million
- Q3 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding IMPL
# of Institutions
1Shares Held
14.4KCall Options Held
0Put Options Held
0About IMPEL PHARMACEUTICALS INC
- Ticker IMPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,738,800
- Market Cap $475K
- Description
- Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...